HEALTHY U MEDICAID

MEDICAL PRIOR AUTHORIZATION REQUEST FORM

ULCERATIVE COLITIS- MEDICAL INFUSED DRUGS

Entyvio®, Inflectra®, Remicade®, Renflexis®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior

Authorization Department at 801-213-1547. Failure to submit clinical documentation to support this request will result in a dismissal of the request. If you have prior authorization questions, please call for assistance: 833-981-0212 Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements. ID#: Date: Member Name: DOB: Gender: Physician: Office Phone: Office Fax: Office Contact: Height/Weight: **HCPCS Code:** Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. **Preferred:** □ Renflexis® (infliximab-abda) Non-preferred: ☐ Entyvio® (vedolizumab), ☐ Inflectra® (infliximab-dyyb), ☐ Remicade® (Infliximab) Dosing/Frequency: If the request is for reauthorization, proceed to reauthorization section **Comments/Notes** Questions Yes No **MODERATE ULCERATIVE COLITIS** 1. Has the member been diagnosed with moderate Ulcerative Please provide documentation Colitis? 2. Is the request made by, or in consultation with, a П П gastroenterologist? 3. Has the member had an adequate trial of at least one high dose Please provide documentation 5-aminosalicylic acid drug (mesalamine, sulfasalazine, etc.) 4. Has the provider performed tuberculosis (TB) screening prior to П П Please provide documentation therapy initiation? 5. If the request is for a tumor necrosis factor inhibitor, has the Please provide documentation П П provider performed hepatitis B screening prior to therapy initiation?

SEVERE ULCERATIVE COLITIS 1. Has the patient been diagnosed with severe Ulcerative Colitis? Please provide documentation 2. Is the request made by, or in consultation with, a gastroenterologist? 3. Has the patient had more than 6 stools per day with blood OR Please provide documentation П П has systemic symptoms (fever, tachycardia, anemia or erythrocyte sedimentation rate > 30mm/h)?

4.	Has the provider performed tuberculosis (TB) screening prior to therapy initiation?			Please provide documentation
5.	If the request is for a tumor necrosis factor inhibitor, has the provider performed hepatitis B screening prior to therapy initiation?			Please provide documentation
FULMINANT COLITIS				
1.	Has the patient been diagnosed with fulminant colitis?			
2.	Is the request made by, or in consultation with, a gastroenterologist?			
3.	Does the member more than 10 bowel movements per day with continuous bleeding OR has colonic dilation, transfusion requirement, or toxicity?			Please provide documentation
4.	Has the provider performed tuberculosis (TB) screening prior to therapy initiation?			Please provide documentation
5.	If the request is for a tumor necrosis factor inhibitor, has the provider performed hepatitis B screening prior to therapy initiation?			Please provide documentation
REAUTHORIZATION				
1.	Is the request for reauthorization of therapy?			
2.	Does updated clinical documentation show a positive response to therapy, such as a decrease or stabilization in the Disease Activity Index (DAI) score?			Please provide documentation
3.	Has the provider performed continued tuberculosis monitoring during therapy?			Please provide documentation
4.	Has the provider performed continued Hepatitis B monitoring in HBV carriers?			Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. Additional information: Physician's Signature:				

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-HU-M025 Origination Date: 01/01/2022 Reviewed/Revised Date: Next Review Date: 01/27/2022 Current Effective Date: 01/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.